Weekly Recap: Q4 2026 Phase III readouts and RSU/warrant grants
Genmab A/S Sponsored ADR (OMXCOP:GMAB) is gearing for potential 2027 launches after pivotal Phase III readouts for Rina-S, petosemtamab and EPKINLY expected in Q4 2026, while granting employees 13,794 RSUs and 13,331 warrants (3—year vest, exercise DKK 2,268).Previous Week RecapThis is an AI-genera…